In this study, ~8% of patients harbored an EGFR amplification in their ctDNA, with EGFR amplifications being most common in colorectal cancer (16% of patients), NSCLC (9%), genitourinary cancers (8%), cutaneous tumors (7%), and breast malignancies (7%) (6). Here, EGFR is linked to colorectal cancer.